Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
- PMID: 20148109
- PMCID: PMC2819237
- DOI: 10.1186/1744-859X-9-6
Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Abstract
Background: Delirium in older adults is a common and serious acute neuropsychiatric syndrome, with core features of inattention and global cognitive impairment. Although antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including sedation, extrapyramidal side effects, and cardiac arrhythmias.
Methods: We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the delirium of patients with Alzheimer's disease.
Results: Delirium Rating Scale (DRS) scores in the two patients with Alzheimer's disease decreased after fluvoxamine monotherapy.
Conclusion: Doctors should consider that fluvoxamine could be an alternative approach in treating delirium in patients with Alzheimer's disease because of the risk of extrapyramidal side effects by antipsychotic drugs.
Similar articles
-
Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases.Ann Gen Psychiatry. 2010 Jun 24;9:28. doi: 10.1186/1744-859X-9-28. Ann Gen Psychiatry. 2010. PMID: 20573265 Free PMC article.
-
Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases.Ann Gen Psychiatry. 2010 Apr 24;9:18. doi: 10.1186/1744-859X-9-18. Ann Gen Psychiatry. 2010. PMID: 20416097 Free PMC article.
-
Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors.Ann Gen Psychiatry. 2010 Mar 6;9:11. doi: 10.1186/1744-859X-9-11. Ann Gen Psychiatry. 2010. PMID: 20205742 Free PMC article.
-
Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.Curr Pharm Des. 2012;18(7):875-83. doi: 10.2174/138161212799436476. Curr Pharm Des. 2012. PMID: 22288409 Review.
-
Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?CNS Neurol Disord Drug Targets. 2009 Dec;8(6):470-4. doi: 10.2174/187152709789824633. CNS Neurol Disord Drug Targets. 2009. PMID: 19702566 Review.
Cited by
-
Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases.Ann Gen Psychiatry. 2010 Jun 24;9:28. doi: 10.1186/1744-859X-9-28. Ann Gen Psychiatry. 2010. PMID: 20573265 Free PMC article.
-
Docking, Interaction Fingerprint, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) of Sigma1 Receptor Ligands, Analogs of the Neuroprotective Agent RC-33.Front Chem. 2019 Jul 11;7:496. doi: 10.3389/fchem.2019.00496. eCollection 2019. Front Chem. 2019. PMID: 31355187 Free PMC article.
-
Roles of sigma-1 receptors in Alzheimer's disease.Int J Clin Exp Med. 2015 Apr 15;8(4):4808-20. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26131055 Free PMC article. Review.
-
Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases.Ann Gen Psychiatry. 2010 Apr 24;9:18. doi: 10.1186/1744-859X-9-18. Ann Gen Psychiatry. 2010. PMID: 20416097 Free PMC article.
-
Improved expression and purification of sigma 1 receptor fused to maltose binding protein by alteration of linker sequence.Protein Expr Purif. 2013 Jun;89(2):203-9. doi: 10.1016/j.pep.2013.03.013. Epub 2013 Apr 3. Protein Expr Purif. 2013. PMID: 23562661 Free PMC article.
References
-
- Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. . 2009;9(3):197–204. - PubMed
-
- Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future. 2009;34:137–146. doi: 10.1358/dof.2009.034.02.1336115. - DOI
LinkOut - more resources
Full Text Sources
